Re: Response to Magos et al.

Epidemiology of Gastroparesis in the United States

“…In the prior electronic medical record-based prevalence study, a greater proportion of patients with type 1 diabetes were found to have a concurrent diagnosis of gastroparesis compared with type 2 diabetes (4.6 vs 1.3%). 6 In the current report, the prevalence of gastroparesis in type 2 diabetes was 9-fold of that in type 1 diabetes. It is also not clear whether the 1 inpatient or 2 outpatient diagnosis criteria refer to the primary diagnosis.…”

“…This study reports 11% of gastroparesis being idiopathic, which is lower than the proportion reported in the GpCRC registries 7 as well as other United States population-based cohorts. 6,8 This could be due to the postsurgical (15%) and drug-induced (12%) gastroparesis reported in the current study. Other prevalence studies, including those from GpCRC, include drug-induced gastroparesis in the idiopathic category.…”

“…Biliary sludge and stones are related to AP, and we demonstrated in a population-based case-control study done in the Olmsted County that gallstones AP is increased in postpartum and in the youngest women. 6 Recently, in a Sicilian population based study of women of childbearing age, we observed an increased incidence of AP only in the first 2 years after delivery: in the first 6 months the increased incidence was 95.37/100,000 compared with 21.61 and 20.02/ 100,000, respectively in the "non pregnant " and "during pregnancy" cohort (P < .001). Once more, this increased incidence was limited to the youngest women and to gallstones AP.…”

Revolutionizing Infection Control: Harnessing MXene‐Based Nanostructures for Versatile Antimicrobial Strategies and Healthcare Advancements

“…[4][5][6][7][8] The advent of nanotechnology represents a groundbreaking advancement in infection control, offering a promising avenue to address the intricate challenges posed by pathogens. [9][10][11] By leveraging the unique properties of materials at the nanoscale, nanotechnology has revolutionized diverse fields, with healthcare being a prominent beneficiary. [12,13] In the realm of infection control, nanotechnology provides a versatile toolbox for precise targeting, improved drug delivery, and innovative antimicrobial strategies, heralding a paradigm shift in the fight against infections.…”